Experimental cancer drug JNJ-70218902 tested in 82 patients

NCT ID NCT04397276

Completed Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested a new drug called JNJ-70218902 in 82 people with advanced solid tumors, including prostate cancer. The drug works by redirecting the body's immune T cells to attack cancer cells. The main goals were to find a safe dose and check for side effects, not yet to prove the drug works against cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JNJ-70218902 (a drug that redirects immune T cells to attack cancer)
What this could lead to: If it works, this could point toward a new treatment option for advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is a very early phase 1 trial focused on safety and dosing, not yet on effectiveness. The drug may cause serious side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma neoplasm prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASMS

Contacts and locations

Locations

BC Cancer Agency - Vancouver BC

Vancouver, British Columbia, V5Z 4E6, Canada
Hosp Univ Fund Jimenez Diaz

Madrid, 28040, Spain
Hosp Univ Hm Sanchinarro

Madrid, 28050, Spain
Hosp Univ Vall D Hebron

Barcelona, 08035, Spain
Princess Margaret Hospital

Toronto, Ontario, M5G 2M9, Canada
Rambam Medical Center

Haifa, 31096, Israel
Sourasky Medical Center

Tel Aviv, 64239, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.